Laura van’t Veer - Concepedia

Author

Laura van’t Veer

Also Known As

A DeMichele, Andy G. Lynch, Anna deFazio, Carolien H. M. van Deurzen, L Esserman, L Van'T Veer, L Van't Veer, L van't Veer, L. Van't Veer, L. van't Veer

157

Publications

17.8K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute University of California, San Francisco The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute University of Chicago

About

Laura van’t Veer is an author at The Netherlands Cancer Institute specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	3.7K
2	Health Sciences	3	3	261
3	Biostatistics	3	3	48
4	Public Health	2	2	122
5	Engineering	1	1	464

Laura van’t Veer

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Pan-cancer analysis of whole genomes Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Nature	2020	3.1K
Landscape of somatic mutations in 560 breast cancer whole-genome sequences Serena Nik‐Zainal, Helen Davies, Johan Staaf, Nature Somatic VariantSomatic MutationsTumor HeterogeneityMedicineGenetics	2016	2.3K
Prophylactic Oophorectomy in Carriers of<i>BRCA1</i>or<i>BRCA2</i>Mutations Timothy R. Rebbeck, Henry T. Lynch, Susan L. Neuhausen, New England Journal of Medicine	2002	1.5K
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer Marc Buyse, Sherene Loi, Laura van’t Veer, JNCI Journal of the National Cancer Institute	2006	1.2K
Clinical Application of the 70-Gene Profile: The MINDACT Trial Fátima Cardoso, Laura van’t Veer, Emiel J. Rutgers, Journal of Clinical Oncology Breast OncologyEngineeringGeneticsPathologyCancer Registration	2008	464
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Susan M. Domchek, Tara M. Friebel, Susan L. Neuhausen, The Lancet Oncology Surgical OncologyOphthalmologyMedicineBilateral Salpingo-oophorectomySurgery	2006	326
1st International consensus guidelines for advanced breast cancer (ABC 1) Fátima Cardoso, A. Costa, Larry Norton, The Breast	2012	295
EMT is the dominant program in human colon cancer Andre Loboda, Michael Nebozhyn, James Watters, BMC Medical Genomics	2011	276
A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients Hongyue Dai, Laura van’t Veer, John R. Lamb, Cancer Research	2005	261
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Rita Nanda, Minetta C. Liu, Christina Yau, Journal of Clinical Oncology Breast OncologyHigh-risk Breast CancerImmunologyPharmacotherapyImmunotherapeutics	2017	208

Page 1